SZABO SCANDIC

Part of Europa Biosite

# Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

## Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

## Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand


**SZABO-SCANDIC HandelsgmbH**

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

# Foralumab

**Cat. No.:** HY-P99199

**CAS No.:** 946415-64-1

**Target:** CD3

**Pathway:** Immunology/Inflammation

**Storage:** Please store the product under the recommended conditions in the Certificate of Analysis.

## BIOLOGICAL ACTIVITY

**Description**

Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells[1].

**$IC_{50}$ & Target**

Target: CD3

**In Vivo**

Foralumab (NI-0401; 0.6-250 μg; p.o.; daily, for 5 d) delays the rejection of B6Rag2$^{-/-}$ skin grafted onto the humanized mice[1].

Foralumab (0.6-250 μg; p.o. and i.h.; daily, for 5 d) prevents skin xenograft rejection in mice with human immune systems[1].

Foralumab (1-15 μg; p.o.; daily, for 5 d) has good bioavailability of intragastric in humanized mice[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

| | |
|---|---|
| Animal Model: | Humanized NOD/SCID IL-2γc$^{-/-}$ mice with Skin grafts (Humanized mice: CD34+ cells are injected intra-hepatically into irradiated (0.9 Gy) NSG pups within 48 hours of birth) [1] |
| Dosage: | 15 μg |
| Administration: | Oral administration; daily, for 5 days and weekly dosing |
| Result: | Showed robust protection against graft rejection and prolongs graft survival.<br>Reduced proliferation of CD8+ T cells and reduced release of TNF.<br>Increased the concentration of IL-10. |

| | |
|---|---|
| Animal Model: | Humanized NOD/SCID IL-2γc$^{-/-}$ mice with Skin grafts (Humanized mice: CD34+ cells are injected intra-hepatically into irradiated (0.9 Gy) NSG pups within 48 hours of birth) [1] |
| Dosage: | 1, 5, 15, 50, and 250 μg (p.o.), 0.6 mg/kg (i.h.) |
| Administration: | Oral administration and subcutaneous injection; daily, for 5 days and weekly dosing |
| Result: | Had tolerant to autologous skin grafts in humanized mice. |

| | |
|---|---|
| Animal Model: | Humanized NOD/SCID IL-2γc$^{-/-}$ mice with Skin grafts (Humanized mice: CD34+ cells are |

| | |
|---|---|
| | injected intra-hepatically into irradiated (0.9 Gy) NSG pups within 48 hours of birth) [1] |
| Dosage: | 0, 5, 10, and 15 μg |
| Administration: | Oral administration and subcutaneous injection; daily, for 5 days and weekly dosing |
| Result: | Increased human Ig on the surface of CD4+ and CD8+ T cells.<br>Had free mAb in the serum of mice |

## REFERENCES

[1]. Ogura M, et, al. Oral treatment with foralumab, a fully human anti-CD3 monoclonal antibody, prevents skin xenograft rejection in humanized mice. Clin Immunol. 2017 Oct;183:240-246.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA